Perpetual Ltd Sells 4,017 Shares of CVS Health Corporation (NYSE:CVS)

Perpetual Ltd lowered its position in CVS Health Corporation (NYSE:CVS - Free Report) by 23.2% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 13,297 shares of the pharmacy operator's stock after selling 4,017 shares during the period. Perpetual Ltd's holdings in CVS Health were worth $901,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of CVS. McIlrath & Eck LLC grew its position in shares of CVS Health by 32.6% during the fourth quarter. McIlrath & Eck LLC now owns 707 shares of the pharmacy operator's stock worth $32,000 after purchasing an additional 174 shares in the last quarter. Horizon Bancorp Inc. IN boosted its holdings in shares of CVS Health by 7.4% during the 1st quarter. Horizon Bancorp Inc. IN now owns 2,610 shares of the pharmacy operator's stock valued at $177,000 after purchasing an additional 180 shares during the last quarter. Coppell Advisory Solutions LLC grew its position in shares of CVS Health by 17.3% during the fourth quarter. Coppell Advisory Solutions LLC now owns 1,282 shares of the pharmacy operator's stock valued at $56,000 after purchasing an additional 189 shares in the last quarter. Strategic Investment Advisors MI increased its holdings in shares of CVS Health by 2.3% in the first quarter. Strategic Investment Advisors MI now owns 8,466 shares of the pharmacy operator's stock worth $574,000 after purchasing an additional 194 shares during the last quarter. Finally, EagleClaw Capital Managment LLC lifted its position in shares of CVS Health by 3.4% in the fourth quarter. EagleClaw Capital Managment LLC now owns 6,135 shares of the pharmacy operator's stock worth $275,000 after buying an additional 200 shares in the last quarter. Hedge funds and other institutional investors own 80.66% of the company's stock.

CVS Health Stock Performance

Shares of CVS Health stock opened at $68.50 on Friday. CVS Health Corporation has a 52 week low of $43.56 and a 52 week high of $72.51. The company has a market capitalization of $86.66 billion, a PE ratio of 16.35, a price-to-earnings-growth ratio of 0.98 and a beta of 0.56. The stock's fifty day moving average is $64.86 and its two-hundred day moving average is $60.86. The company has a quick ratio of 0.63, a current ratio of 0.82 and a debt-to-equity ratio of 0.77.

CVS Health (NYSE:CVS - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The pharmacy operator reported $2.25 EPS for the quarter, topping the consensus estimate of $1.62 by $0.63. CVS Health had a net margin of 1.39% and a return on equity of 10.59%. The company had revenue of $94.59 billion for the quarter, compared to the consensus estimate of $93.07 billion. During the same quarter last year, the firm posted $1.31 EPS. The firm's revenue was up 7.0% compared to the same quarter last year. As a group, analysts expect that CVS Health Corporation will post 5.89 earnings per share for the current year.

Insider Buying and Selling at CVS Health

In other news, Director Guy P. Sansone purchased 1,570 shares of the business's stock in a transaction dated Thursday, June 5th. The shares were purchased at an average price of $63.70 per share, for a total transaction of $100,009.00. Following the completion of the purchase, the director now owns 12,007 shares in the company, valued at approximately $764,845.90. This represents a 15.04% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. 1.22% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

CVS has been the subject of several research analyst reports. Robert W. Baird raised their price target on CVS Health from $51.00 to $71.00 and gave the company a "neutral" rating in a report on Tuesday, April 15th. Royal Bank Of Canada boosted their price target on shares of CVS Health from $74.00 to $81.00 and gave the stock an "outperform" rating in a research report on Monday, May 5th. Cowen reiterated a "buy" rating on shares of CVS Health in a research report on Monday, May 5th. Barclays set a $79.00 target price on shares of CVS Health and gave the stock an "overweight" rating in a report on Monday, June 2nd. Finally, Truist Financial increased their price target on shares of CVS Health from $82.00 to $84.00 and gave the company a "buy" rating in a report on Monday, May 12th. Two equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $74.75.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corporation (NYSE:CVS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.